Challenges and opportunities in targeting the menin-MLL interaction

Future Medicinal Chemistry

Volumn 6, Issue 4, 2014, Pages 447-462

  Cierpicki, Tomasz ^a   Grembecka, Jolanta ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE METHYLTRANSFERASE; LENS EPITHELIUM DERIVED GROWTH FACTOR; METHIONINE; MIXED LINEAGE LEUKEMIA PROTEIN; PEPTIDOMIMETIC AGENT; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR HOXA9;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER PROGNOSIS; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 11Q; CHROMOSOME BAND; CHROMOSOME REARRANGEMENT; CRYSTAL STRUCTURE; DRUG TARGETING; EVENT FREE SURVIVAL; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HOX GENE; HUMAN; LEUKEMIA CELL; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SUMOYLATION; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

BINDING SITES; HUMANS; LEUKEMIA; MOLECULAR DOCKING SIMULATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PEPTIDOMIMETICS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84896987501     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.214     Document Type: Review

References (94)

1. Pui CH, Gaynon PS, Boyett JM et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359(9321), 1909-1915. (2002).
2. Liu H, Cheng EH, Hsieh JJ. MLL fusions: pathways to leukemia. Cancer Biol. Ther. 8(13), 1204-1211 (2009).
3. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer. 33(4), 331-345 (2002).
4. Popovic R, Zeleznik-Le NJ. MLL: how complex does it get? J. Cell. Biochem. 95(2), 234-242 (2005).
5. Meyer C, Schneider B, Jakob S et al. The MLL recombinome of acute leukemias. Leukemia 20(5), 777-784 (2006).
6. Dou Y, Hess JL. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int. J. Hematol. 87(1), 10-18 (2008).
7. Zeisig BB, Milne T, Garcia-Cuellar MP et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol. Cell. Biol. 24(2), 617-628 (2004).
8. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer. Res. 65(24), 11367-11374 (2005).
9. Milne TA, Dou Y, Martin ME, Brock HW, Roeder RG, Hess JL. MLL associates specifically with a subset of transcriptionally active target genes. Proc. Natl Acad. Sci. USA 102(41), 14765-14770 (2005).
10. Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 21(21), 2762-2774 (2007).
11. Owens BM, Hawley RG. HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells. 20(5), 364-379. (2002).
12. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene. 26(47), 6766-6776. (2007).
13. Rice KL, Licht JD. HOX deregulation in acute myeloid leukemia. J. Clin. Invest. 117(4), 865-868. (2007).
14. Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30(1), 41-47 (2002).
15. Ayton PM, Cleary ML: Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 17(18), 2298-2307 (2003).
16. Slany RK. When epigenetics kills: MLL fusion proteins in leukemia. Hematol. Oncol. 23(1), 1-9 (2005).
17. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123(2), 207-218 (2005).
18. Chen YX, Yan J, Keeshan K et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc. Natl Acad. Sci. USA 103(4), 1018-1023 (2006).
19. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276(5311), 404-407 (1997).
20. Guru SC, Goldsmith PK, Burns AL et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl Acad. Sci. USA 95(4), 1630-1634. (1998).
21. Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 67(15), 7275-7283 (2007).
22. Grembecka J, Belcher AM, Hartley T, Cierpicki T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J. Biol. Chem. 285(52), 40690-40698 (2010).
23. Hughes CM, Rozenblatt-Rosen O, Milne TA et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell. 13(4), 587-597. (2004).
24. Grembecka J, He S, Shi A et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 8(3), 277-284 (2012).
25. Shi A, Murai MJ, He S et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 120(23), 4461-4469 (2012).
26. Yokoyama A, Wang Z, Wysocka J et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol. 24(13), 5639-5649. (2004).
27. Cosgrove MS, Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J. 277(8), 1832-1842 (2010).
28. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 94(7), 984-993 (2009).
29. Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu. Rev. Biochem. 81, 65-95 (2012).
30. Dou Y, Milne TA, Ruthenburg AJ et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat. Struct. Mol. Biol. 13(8), 713-719 (2006).
31. Dou Y, Milne TA, Tackett AJ et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121(6), 873-885 (2005).
32. Milne TA, Hughes CM, Lloyd R et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl Acad. Sci. USA 102(3), 749-754 (2005).
33. Onodera A, Yamashita M, Endo Y et al. STAT6-mediated displacement of polycomb by trithorax complex establishes long-term maintenance of GATA3 expression in T helper type 2 cells. J. Exp. Med. 207(11), 2493-2506 (2010).
34. Thiel AT, Blessington P, Zou T et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 17(2), 148-159 (2010).
35. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14(1), 36-46 (2008).
36. Van Nuland R, Smits AH, Pallaki P, Jansen PW, Vermeulen M, Timmers HT. Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes. Mol. Cell. Biol. 33(10), 2067-2077 (2013).
37. Huang J, Gurung B, Wan B et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482(7386), 542-546 (2012).
38. Agarwal SK, Jothi R. Genome-wide characterization of menin-dependent H3K4me3 reveals a specific role for menin in the regulation of genes implicated in MEN1-like tumors. PLoS ONE 7(5), e37952 (2012).
39. Scacheri PC, Davis S, Odom DT et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2(4), e51 (2006).
40. Li BE, Gan T, Meyerson M, Rabbitts TH, Ernst P. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood 122(12), 2039-2046 (2013).
41. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat. Rev. Cancer. 5(5), 367-375. (2005).
42. Trump D, Farren B, Wooding C et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89(9), 653-669 (1996).
43. Pannett AA, Thakker RV. Multiple endocrine neoplasia type 1. Endocr. Relat. Cancer 6(4), 449-473 (1999).
44. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68(4), 820-823 (1971).
45. Crabtree JS, Scacheri PC, Ward JM et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. Natl Acad. Sci. USA 98(3), 1118-1123 (2001).
46. Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol. Endocrinol. 17(9), 1880-1892 (2003).
47. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 29(1), 22-32 (2008).
48. Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I, Tsukada T. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol. Cell. Biol. 24(15), 6569-6580 (2004).
49. Shimazu S, Nagamura Y, Yaguchi H, Ohkura N, Tsukada T. Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. Cancer Sci. 102(11), 2097-2102 (2011).
50. Murai MJ, Chruszcz M, Reddy G, Grembecka J, Cierpicki T. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J. Biol. Chem. 286(36), 31742-31748 (2011).
51. Agarwal SK, Guru SC, Heppner C et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96(1), 143-152 (1999).
52. Heppner C, Bilimoria KY, Agarwal SK et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 20(36), 4917-4925. (2001).
53. Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc. Natl Acad. Sci. USA 98(7), 3837-3842 (2001).
54. Kim H, Lee JE, Cho EJ, Liu JO, Youn HD. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res. 63(19), 6135-6139 (2003).
55. Dreijerink KM, Mulder KW, Winkler GS, Hoppener JW, Lips CJ, Timmers HT. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 66(9), 4929-4935 (2006).
56. Imachi H, Murao K, Dobashi H et al. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res. Treat. 122(2), 395-407 (2010).
57. Schnepp RW, Hou Z, Wang H et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res. 64(18), 6791-6796 (2004).
58. Jin S, Mao H, Schnepp RW et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 63(14), 4204-4210 (2003).
59. Sukhodolets KE, Hickman AB, Agarwal SK et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol. Cell. Biol. 23(2), 493-509 (2003).
60. Balogh K, Patocs A, Hunyady L, Racz K. Menin dynamics and functional insight: take your partners. Mol. Cell. Endocrinol. 326(1-2), 80-84 (2010).
61. Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem. Sci. 38(8), 394-402 (2013).
62. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol. Cell. Endocrinol. doi:10.1016/j. mce.2013.08.002 (2013) (Epub ahead of print).
63. Yang Y, Hua X. In search of tumor suppressing functions of menin. Mol. Cell Endocrinol. 265-266, 34-41 (2007).
64. Karges W, Maier S, Wissmann A, Dralle H, Dosch HM, Boehm BO. Primary structure, gene expression and chromosomal mapping of rodent homologs of the MEN1 tumor suppressor gene. Biochim. Biophys. Acta 1446(3), 286-294 (1999).
65. Papaconstantinou M, Maslikowski BM, Pepper AN, Bedard PA. Menin: the protein behind the MEN1 syndrome. Adv. Exp. Med. Biol. 668, 27-36 (2009).
66. Gray FL, Murai MJ, Grembecka J, Cierpicki T. Detection of Disordered Regions in Globular Proteins Using (1)(3)C-detected NMR. Protein Sci. 21(12), 1954-1960 (2012).
67. Macconaill LE, Hughes CM, Rozenblatt-Rosen O, Nannepaga S, Meyerson M. Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Mol. Cancer Res. 4(10), 793-801 (2006).
68. Francis J, Lin W, Rozenblatt-Rosen O, Meyerson M. The menin tumor suppressor protein is phosphorylated in response to DNA damage. PLoS ONE 6(1), e16119 (2011).
69. Feng ZJ, Gurung B, Jin GH, Yang XL, Hua XX. SUMO modification of menin. Am. J. Cancer Res. 3(1), 96-106 (2013).
70. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 34(Web Server issue), W116-W118 (2006).
71. White AW, Westwell AD, Brahemi G. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Rev. Mol. Med. 10, e8 (2008).
72. Zhou H, Liu L, Huang J et al. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. J. Med. Chem. 56(3), 1113-1123 (2013).
73. Manka J, Daniels RN, Dawson E et al. Inhibitors of the menin-mixed lineage leukemia (MLL) interaction. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda, MD, USA (2013).
74. Olsen JA, Banner DW, Seiler P et al. Fluorine interactions at the thrombin active site: protein backbone fragments H-C(alpha)-C=O comprise a favorable C-F environment and interactions of C-F with electrophiles. Chembiochem 5(5), 666-675 (2004).
75. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378(6556), 505-508 (1995).
76. Guenther MG, Jenner RG, Chevalier B et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc. Natl Acad. Sci. USA 102(24), 8603-8608 (2005).
77. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc. Natl Acad. Sci. USA 95(18), 10632-10636 (1998).
78. Mishra BP, Ansari KI, Mandal SS. Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle. FEBS J. 276(6), 1629-1640 (2009).
79. Ansari KI, Hussain I, Das HK, Mandal SS. Overexpression of human histone methylase MLL1 upon exposure to a food contaminant mycotoxin, deoxynivalenol. FEBS J. 276(12), 3299-3307 (2009).
80. Ansari KI, Kasiri S, Mandal SS. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo. Oncogene 32(28), 3359-3370 (2013).
81. Takeda S, Liu H, Sasagawa S et al. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J. Clin. Invest. 123(7), 3154-3165 (2013).
82. Xu B, Li SH, Zheng R et al. Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription. Proc. Natl Acad. Sci. USA 110(43), 17480-17485 (2013).
83. Gallo M, Ho J, Coutinho FJ et al. A tumorigenic MLL-homeobox network in human glioblastoma stem cells. Cancer Res. 73(1), 417-427 (2013).
84. Heddleston JM, Wu Q, Rivera M et al. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ. 19(3), 428-439 (2012).
85. Milne TA, Kim J, Wang GG et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol. Cell. 38(6), 853-863 (2010).
86. Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer. Res. 70(21), 8726-8735 (2010).
87. Glaser S, Schaft J, Lubitz S et al. Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development 133(8), 1423-1432 (2006).
88. Lubitz S, Glaser S, Schaft J, Stewart AF, Anastassiadis K. Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase Mll2. Mol. Biol. Cell. 18(6), 2356-2366 (2007).
89. Bogershausen N, Bruford E, Wollnik B. Skirting the pitfalls: a clear-cut nomenclature for H3K4 methyltransferases. Clin. Genet. 83(3), 212-214 (2013).
90. Huntsman DG, Chin SF, Muleris M et al. MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene 18(56), 7975-7984 (1999).
91. Natarajan TG, Kallakury BV, Sheehan CE et al. Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon. Cancer Cell Int. 10, 13 (2010).
92. Ansari KI, Kasiri S, Mishra BP, Mandal SS. Mixed lineage leukaemia-4 regulates cell-cycle progression and cell viability and its depletion suppresses growth of xenografted tumour in vivo. Br. J. Cancer 107(2), 315-324 (2012).
93. Imachi H, Yu X, Nishiuchi T, Miyai Y, Masugata H, Murao K. Raloxifene inhibits menin-dependent estrogen receptor activation in breast cancer cells. J. Endocrinol. Invest. 34(11), 813-815 (2011).
94. Smith MC, Gestwicki JE. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert. Rev. Mol. Med. 14, e16 (2012).